Inventor
IRVING L. WEISSMAN
Inventor
US
Overview
Patents· 43 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes24%
C07KPeptides23%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
C12NMicroorganisms or enzymes7%
G01NInvestigating or analysing materials by determining their chemical or physical properties7%
Y02ATechnologies for adaptation to climate change6%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%
C12YEnzymes1%
G16HHealthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data1%
H04LTransmission of digital information, e.g. telegraphic communication1%
PatentTitleYear
12,589,114GABA agonists and antagonists affect differentiation of hematopoietic stem cells and megakaryocyte progenitors202612,410,259CD47 targeted therapies for the treatment of infectious disease202512,370,243Non-genotoxic conditioning regimen for stem cell transplantation202512,318,448Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells202512,274,746Dosing parameters for CD47 targeting therapies to hematologic malignancies202512,258,399Methods for achieving therapeutically effective doses of anti-CD47 agents202512,258,403Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody202512,233,093Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling202512,195,532High affinity SIRP-alpha reagents and methods of using202512,194,093Dosing parameters for CD47 targeting therapies to hematologic malignancies202512,162,939Methods for manipulating phagocytosis mediated by CD47202412,091,456Targeting aneurysm disease by modulating phagocytosis pathways202412,037,402Treatment of cancer with dual targeting of CD47 and EGFR202412,030,944Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist202411,965,034Antifibrotic activity of CD47 blockade in the liver202411,905,333Selective immunodepletion of endogenous stem cell niche for engraftment202411,814,419High affinity PD-1 agents and methods of use202311,807,684Humanized and chimeric monoclonal antibodies to CD47202311,780,918Markers of acute myeloid leukemia stem cells202311,780,931CD47 targeted therapies for the treatment of infectious disease202311,773,165Markers of acute myeloid leukemia stem cells202311,766,454Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells202311,760,810Modified immunoglobulin hinge regions to reduce hemagglutination202311,760,800Markers of acute myeloid leukemia stem cells202311,718,670Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer202311,718,675Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy202311,642,379Hematopoietic stem cell engraftment202311,608,377Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist202311,603,404Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody202311,529,391Reversing deficient hedgehog signaling restores deficient skeletal regeneration202211,518,806Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody202211,472,878Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer202211,459,388Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance202211,419,897Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling202211,377,495Markers of acute myeloid leukemia stem cells202211,369,641Identification and uses of vasculature forming progenitor cells and progenitor cell combinations202211,286,301Antifibrotic activity of CD47 blockade202211,253,588Combination therapy for treatment of coronary artery disease202211,230,607CD47 targeted therapies for the treatment of infectious disease202211,208,481High affinity SIRP-alpha reagents and methods of using202111,154,600Use of anti-CD47 agents to enhance immunization202111,141,480Dosing parameters for CD47 targeting therapies to hematologic malignancies202111,136,391Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to UNIV LELAND STANFORD JUNIOR (43)· patent assignee history
2021–2023Patents assigned to FORTY SEVEN INC (2)· patent assignee history
2021–2026Based in US· patent location history
2022–2025Patents assigned to UNIV CALIFORNIA (4)· patent assignee history
2022–2025Patents assigned to US HEALTH (3)· patent assignee history
2025Patents assigned to FORTY SEVEN LLC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV LELAND STANFORD JUNIOR | 43 | 2021–2026 |
| UNIV CALIFORNIA | 4 | 2022–2025 |
| US HEALTH | 3 | 2022–2025 |
| FORTY SEVEN INC | 2 | 2021–2023 |
| FORTY SEVEN LLC | 2 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 43 | 2021–2026 |